{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:19:08Z","timestamp":1790302748893,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM17\/00044"],"award-info":[{"award-number":["CM17\/00044"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.nmd.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T11:51:39Z","timestamp":1555588299000},"page":"517-524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II"],"prefix":"10.1016","volume":"29","author":[{"given":"A.L.","family":"Frongia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Natera-de Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Borr\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Padr\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Armas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carrera-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Exp\u00f3sito-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cuadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2019.04.003_bib0001","series-title":"Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach","first-page":"117","article-title":"Spinal muscular atrophies","author":"Darras","year":"2015"},{"key":"10.1016\/j.nmd.2019.04.003_bib0002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum Mutat"},{"key":"10.1016\/j.nmd.2019.04.003_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.24497","article-title":"Spinal muscular atrophy: diagnosis and management in a new therapeutic era","volume":"51","author":"Arnold","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.04.003_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet."},{"key":"10.1016\/j.nmd.2019.04.003_bib0005","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1136\/jmg.40.4.e39","article-title":"Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling","volume":"40","author":"Cusin","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0006","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0007","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0008","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting. (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0009","unstructured":"Prior TW, Finanger E. Spinal muscular atrophy. 2000 Feb 24 [updated 2016 Dec 22]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Eds. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132018. Available fromhttp:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1352\/."},{"key":"10.1016\/j.nmd.2019.04.003_bib0010","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0011","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1086\/302369","article-title":"Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling","volume":"64","author":"Wirth","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0013","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0014","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.nmd.2012.11.004","article-title":"Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations","volume":"23","author":"Burke","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pediatrneurol.2012.04.022","article-title":"Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol","volume":"47","author":"Chan","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0016","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes","volume":"85","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0017","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1042\/cs0830615","article-title":"Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men","volume":"83","author":"Martineau","year":"1992","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.nmd.2019.04.003_bib0018","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes","volume":"85","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0019","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/hmg\/ddy062","article-title":"The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes","volume":"27","author":"McMacken","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1055\/s-2004-821173","article-title":"Pilot trial of salbutamol in central core and multi-minicore diseases","volume":"35","author":"Messina","year":"2004","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.nmd.2019.04.003_bib0021","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.50.5.1402","article-title":"Open-label clinical trial of albuterol in facioscapulohumeral muscular dystrophy","volume":"50","author":"Kissel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0022","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0023","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/01.WNL.0000134660.30793.1F","article-title":"Strength training and albuterol in facioscapulohumeral muscular dystrophy","volume":"63","author":"van der Kooi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0024","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.apmr.2008.12.027","article-title":"Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"90","author":"Payan","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2019.04.003_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"\u03b22 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2019.04.003_bib0026","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/01.WNL.0000118530.71646.0F","article-title":"Pilot trial of albuterol in Duchenne and Becker muscular dystrophy","volume":"62","author":"Fowler","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0027","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1212\/01.WNL.0000287070.00149.a9","article-title":"Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy","volume":"70","author":"Skura","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0028","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2019.04.003_bib0029","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/mus.25102","article-title":"Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study","volume":"54","author":"Giovannetti","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.04.003_bib0031","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","article-title":"Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy","volume":"73","author":"Khirani","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells","volume":"45","author":"Angelozzi","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0033","first-page":"351","article-title":"Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells","volume":"4","author":"Harahap","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.nmd.2019.04.003_bib0034","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2019.04.003_bib0035","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.nmd.2018.07.013","article-title":"Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy?","volume":"28","author":"Pera","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0036","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26-28 June 92, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0038","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2019.04.003_bib0039","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.nmd.2012.06.245","article-title":"S.P.6 Exploratory Rasch analysis of the EK2 scale used in a population of Duchenne muscular dystrophy (DMD)","volume":"22","author":"Mayhew","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0040","first-page":"344","article-title":"Evolution of functional capacity, assessed with the Egen Klassifikation scale, in the Spanish population with spinal muscular atrophy or Duchenne muscular dystrophy. A three year longitudinal study","volume":"61","author":"Fagoaga","year":"2015","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0041","first-page":"657","article-title":"Hammersmith functional rating scale for children with spinal muscular atrophy. Validation of the Spanish version","volume":"53","author":"Febrer","year":"2011","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0042","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2019.04.003_bib0043","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0044","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":"Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year","volume":"68","author":"Kaufmann","year":"2011","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2019.04.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121799","article-title":"Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2019.04.003_bib0046","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2005.11.010","article-title":"Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study","volume":"16","author":"Mercuri","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2019.04.003_bib0047","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0887-8994(93)90082-N","article-title":"Prospective study of spinal muscular atrophy before age 6 years. DCN\/SMA Group","volume":"9","author":"Iannaccone","year":"1993","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2019.04.003_bib0048","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.nmd.2014.01.003","article-title":"Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients","volume":"24","author":"Mazzone","year":"2014","journal-title":"Neuromuscul Disord"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618305443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618305443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:07:54Z","timestamp":1760774874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896618305443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0960896618305443"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2019.04.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}